GW 215864

Drug Profile

GW 215864

Alternative Names: GR 215864X; GW 215864X

Latest Information Update: 31 Dec 2000

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Class Antiasthmatics
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Asthma; Rhinitis

Most Recent Events

  • 31 Dec 2000 Discontinued-I for Rhinitis in United Kingdom (Intranasal)
  • 07 Feb 2000 Discontinued-II for Asthma in United Kingdom (Inhalation)
  • 07 Feb 2000 Phase-I clinical trials for Rhinitis in United Kingdom (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top